BBIO: Encaleret Phase 3 CALIBRATE trial results in ADH1
BBIO says its Encaleret increased bone turnover and improved participant-reported symptoms in the Phase 3 CALIBRATE trial in ADH1.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.